A clinical trial published in 2022 found that an older GLP-1 drug called exenatide also reduced drinking among those who had both alcohol use disorder and obesity
At the party, they discussed the therapeutic potential of GLP-1
Peptides such as HGH-191AA, IGF-1 LR3, MK-677, and BPC-157 are also evaluated for their specific roles in skeletal strength and joint recovery within research studies
The absence of effects on IGF-1, glucose metabolism, and tissue growth reduces concerns about long-term hormonal consequences, but prudent medical oversight remains appropriate for any extended peptide use
The variation reflects differences in pharmacy overhead, testing protocols, ingredient sourcing, and profit margins